IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Lonza Buys Five US Sites From Merck

Contract drug manufacturer Lonza agreed to buy five US manufacturing sites from Merck KGaA to expand its production of advanced cancer and gene therapies. The deal more than doubles Lonza's US footprint and is expected to close in mid-2027.

Xurve View
Insights:
FILE PHOTO: The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/File Photo

LONZA GROUP AG-REG agreed to buy five manufacturing sites in the United States from MERCK KGAA for 350 million Swiss francs ($428 million), doubling its American footprint.